P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Pipeline Review, H2 2018
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Pipeline Review, H2 2018
SUMMARY
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) pipeline Target constitutes close to 6 molecules. The latest report P Selectin - Pipeline Review, H2 2018, outlays comprehensive information on the P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - P-selectin is a protein encoded by the SELP gene. P-selectin functions as a cell adhesion molecule (CAM) on the surfaces of activated endothelial cells. In unactivated endothelial cells, it is stored in granules called Weibel-Palade bodies. In unactivated platelets P-selectin is stored in ?-granules. P-selectin plays an essential role in the initial recruitment of leukocytes (white blood cells) to the site of injury during inflammation.
The molecules developed by companies in Phase III, Preclinical, Discovery and Unknown stages are 2, 2, 1 and 1 respectively. Report covers products from therapy areas Cardiovascular, Hematological Disorders, Central Nervous System, Ear Nose Throat Disorders, Gastrointestinal, Immunology, Mouth and Dental Disorders and Oncology which include indications Vaso-Occlusive Crisis Associated With Sickle Cell Disease, Sickle Cell Disease, Inflammation, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Oral Mucositis, Periodontitis and Rhino sinusitis.
Furthermore, this report also reviews key players involved in P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) pipeline Target constitutes close to 6 molecules. The latest report P Selectin - Pipeline Review, H2 2018, outlays comprehensive information on the P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - P-selectin is a protein encoded by the SELP gene. P-selectin functions as a cell adhesion molecule (CAM) on the surfaces of activated endothelial cells. In unactivated endothelial cells, it is stored in granules called Weibel-Palade bodies. In unactivated platelets P-selectin is stored in ?-granules. P-selectin plays an essential role in the initial recruitment of leukocytes (white blood cells) to the site of injury during inflammation.
The molecules developed by companies in Phase III, Preclinical, Discovery and Unknown stages are 2, 2, 1 and 1 respectively. Report covers products from therapy areas Cardiovascular, Hematological Disorders, Central Nervous System, Ear Nose Throat Disorders, Gastrointestinal, Immunology, Mouth and Dental Disorders and Oncology which include indications Vaso-Occlusive Crisis Associated With Sickle Cell Disease, Sickle Cell Disease, Inflammation, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Oral Mucositis, Periodontitis and Rhino sinusitis.
Furthermore, this report also reviews key players involved in P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP)
- The report reviews P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics and enlists all their major and minor projects
- The report assesses P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Overview
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Companies Involved in Therapeutics Development
Global Blood Therapeutics Inc
Novartis AG
Pfizer Inc
Tumorend LLC
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Drug Profiles
crizanlizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inclacumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rivipansel sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit P and L Selectins for Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Dormant Products
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Discontinued Products
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Product Development Milestones
Featured News & Press Releases
Jun 14, 2018: New Hope in the Fight Against Sickle Cell Disease
Dec 11, 2017: Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
Feb 01, 2017: A multiple drug approach to preventing sickle cell crisis
Dec 03, 2016: Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel
Oct 29, 2015: Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology
Jun 23, 2015: GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel
Jun 23, 2015: Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease
Apr 07, 2015: GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015
Mar 03, 2015: GlycoMimetics Announces Publication of Phase 2 Data for Rivipansel in Sickle Cell Disease
Dec 09, 2014: GlycoMimetics Highlights Potential Therapeutic Benefits of Its Novel E-Selectin Antagonist Rivipansel at 56th ASH Annual Meeting
Nov 06, 2014: GlycoMimetics Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting
Sep 26, 2014: GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With Rivipansel
Jul 01, 2014: GlycoMimetics Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Rivipansel (GMI-1070)
May 21, 2014: GlycoMimetics Receives $15 Million Payment from Pfizer in Connection with Planned Initiation of Phase 3 Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Overview
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Companies Involved in Therapeutics Development
Global Blood Therapeutics Inc
Novartis AG
Pfizer Inc
Tumorend LLC
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Drug Profiles
crizanlizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inclacumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rivipansel sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit P and L Selectins for Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Dormant Products
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Discontinued Products
P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) - Product Development Milestones
Featured News & Press Releases
Jun 14, 2018: New Hope in the Fight Against Sickle Cell Disease
Dec 11, 2017: Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
Feb 01, 2017: A multiple drug approach to preventing sickle cell crisis
Dec 03, 2016: Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study
Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel
Oct 29, 2015: Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology
Jun 23, 2015: GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel
Jun 23, 2015: Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease
Apr 07, 2015: GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015
Mar 03, 2015: GlycoMimetics Announces Publication of Phase 2 Data for Rivipansel in Sickle Cell Disease
Dec 09, 2014: GlycoMimetics Highlights Potential Therapeutic Benefits of Its Novel E-Selectin Antagonist Rivipansel at 56th ASH Annual Meeting
Nov 06, 2014: GlycoMimetics Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting
Sep 26, 2014: GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With Rivipansel
Jul 01, 2014: GlycoMimetics Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Rivipansel (GMI-1070)
May 21, 2014: GlycoMimetics Receives $15 Million Payment from Pfizer in Connection with Planned Initiation of Phase 3 Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Global Blood Therapeutics Inc, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by Tumorend LLC, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Global Blood Therapeutics Inc, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by Tumorend LLC, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Global Blood Therapeutics Inc
Novartis AG
Pfizer Inc
Tumorend LLC
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Global Blood Therapeutics Inc
Novartis AG
Pfizer Inc
Tumorend LLC
